CS238635B2 - Production method of new derivatives of omega-cyan-1-omega-diphenylazaalkane - Google Patents

Production method of new derivatives of omega-cyan-1-omega-diphenylazaalkane Download PDF

Info

Publication number
CS238635B2
CS238635B2 CS827838A CS783882A CS238635B2 CS 238635 B2 CS238635 B2 CS 238635B2 CS 827838 A CS827838 A CS 827838A CS 783882 A CS783882 A CS 783882A CS 238635 B2 CS238635 B2 CS 238635B2
Authority
CS
Czechoslovakia
Prior art keywords
cyano
methylase
methoxyphenyl
analysis
calculated
Prior art date
Application number
CS827838A
Other languages
Czech (cs)
English (en)
Inventor
Oskar Ehrmann
Manfred Raschack
Josef Gries
Rolf Kretzschmar
Hans D Lehmann
Ludwig Friedrich
Dirk Wuppermann
Frank Zimmermann
Werner Seitz
Hans J Treiber
Ferdinand Dengel
Wolfram Frank
Hans-Georg Kurbjuweit
Claus D Mueller
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of CS238635B2 publication Critical patent/CS238635B2/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
CS827838A 1981-04-10 1982-04-06 Production method of new derivatives of omega-cyan-1-omega-diphenylazaalkane CS238635B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3114497 1981-04-10
DE19813144150 DE3144150A1 (de) 1981-04-10 1981-11-06 (omega)-cyan-1,(omega)-diphenyl-azaalkan-derivate, ihre herstellung und diese enthaltende arzneimittel

Publications (1)

Publication Number Publication Date
CS238635B2 true CS238635B2 (en) 1985-12-16

Family

ID=25792602

Family Applications (4)

Application Number Title Priority Date Filing Date
CS827839A CS238636B2 (en) 1981-04-10 1982-04-06 Production method of derivatives of omega-cyan-1,omega-diphenylazaalkane
CS827838A CS238635B2 (en) 1981-04-10 1982-04-06 Production method of new derivatives of omega-cyan-1-omega-diphenylazaalkane
CS822458A CS238621B2 (en) 1981-04-10 1982-04-06 Production method of new derivatives of omega-cyan-1,omega-diphenylazaalcane
CS827837A CS238634B2 (en) 1981-04-10 1982-04-06 Production method of new derivatives of omega-cyan-1-omega-diphenylazaalkane

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CS827839A CS238636B2 (en) 1981-04-10 1982-04-06 Production method of derivatives of omega-cyan-1,omega-diphenylazaalkane

Family Applications After (2)

Application Number Title Priority Date Filing Date
CS822458A CS238621B2 (en) 1981-04-10 1982-04-06 Production method of new derivatives of omega-cyan-1,omega-diphenylazaalcane
CS827837A CS238634B2 (en) 1981-04-10 1982-04-06 Production method of new derivatives of omega-cyan-1-omega-diphenylazaalkane

Country Status (19)

Country Link
US (1) US4438131A (es)
EP (1) EP0064158B1 (es)
AU (1) AU546383B2 (es)
CA (1) CA1184186A (es)
CS (4) CS238636B2 (es)
DD (1) DD201778A5 (es)
DE (2) DE3144150A1 (es)
DK (1) DK156513C (es)
ES (4) ES511260A0 (es)
FI (1) FI76550C (es)
GB (1) GB2100252B (es)
GR (1) GR75531B (es)
HU (1) HU186058B (es)
IE (1) IE54044B1 (es)
MX (1) MX9203501A (es)
NO (1) NO152129C (es)
PH (1) PH19739A (es)
SG (1) SG78584G (es)
SU (1) SU1308195A3 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3344755A1 (de) * 1983-12-10 1985-06-20 Basf Ag, 6700 Ludwigshafen 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten
DE3433383A1 (de) * 1984-09-12 1986-03-20 Boehringer Mannheim Gmbh, 6800 Mannheim Neue phenyl-acetonitril-derivate
US4612329A (en) * 1984-10-17 1986-09-16 Hokuriku Pharmaceutical Co., Ltd. Pharmaceutical alpha-aminoalkyl-alpha-alkylphenylacetonitriles
US4760089A (en) * 1985-09-09 1988-07-26 Smithkline Beckman Corporation Irreversible dopamine-β-hydroxylase inhibitors
FR2588258B1 (fr) * 1985-10-04 1989-12-15 Adir Nouveaux derives d'amino-5 valeronitrile, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
DE3535949A1 (de) * 1985-10-09 1987-04-09 Basf Ag Kombinationspraeparat
DE3535950A1 (de) * 1985-10-09 1987-04-09 Basf Ag Kombinationspraeparat
EP0271591B1 (de) * 1986-12-13 1989-09-20 BASF Aktiengesellschaft Kombinationspräparat
NZ217960A (en) * 1985-10-18 1990-01-29 Searle & Co Bicyclo-substituted phenylacetonitriles and pharmaceutical compositions
US4593042A (en) * 1985-10-18 1986-06-03 G. D. Searle & Co. Bicyclo-substituted phenylacetonitrile derivatives
DE3542994A1 (de) * 1985-12-05 1987-06-11 Basf Ag Basisch substituierte phenylacetaldehyde, ihre herstellung und diese enthaltende arzneimittel
DE3603032A1 (de) * 1986-01-31 1987-08-06 Basf Ag Basisch substituierte phenylacetonitrile, ihre herstellung und diese enthaltende arzneimittel
CS258534B1 (en) * 1986-07-18 1988-08-16 Ludvik Blaha Derivatives of valeronitrile and method of their preparation
DE3634389A1 (de) * 1986-10-09 1988-04-21 Knoll Ag Verwendung von anipamil
DE3642331A1 (de) * 1986-12-11 1988-06-23 Basf Ag Basisch substituierte phenylacetonitrile, ihre herstellung und diese enthaltende arzneimittel
US5486539A (en) * 1989-12-21 1996-01-23 G. D. Searle & Co. Method of using phenylacetonitrilealkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
US5247119A (en) * 1990-12-12 1993-09-21 G. D. Searle & Co. Phenylacetonitrilehydroxyalkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
CS164891A3 (en) * 1991-05-31 1992-12-16 Vyzk Ustav Farm Biochem Sp N-arylalkyl derivatives of 2-aminomethyl-1,4-benzodioxan, and process forpreparing thereof
DE4124252A1 (de) * 1991-07-22 1993-01-28 Knoll Ag Verfahren zur herstellung einer sterilfiltrierbaren wirkstoffloesung
DE4234000A1 (de) * 1992-10-09 1994-04-14 Knoll Ag Verfahren zur Racemattrennung von Anipamil
ES2498047T3 (es) 2007-06-20 2014-09-24 Milestone Pharmaceuticals Inc. Bloqueantes de los canales de calcio de fenilalquilamina de acción corta y usos de los mismos
KR102255108B1 (ko) 2013-03-08 2021-05-24 노파르티스 아게 활성제의 전달을 위한 지질 및 지질 조성물
US9504747B2 (en) 2013-03-08 2016-11-29 Novartis Ag Lipids and lipid compositions for the delivery of active agents
WO2016010840A1 (en) 2014-07-16 2016-01-21 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA916719A (en) 1972-12-12 Dengel Ferdinand Basically substituted phenylacetonitriles and method for their preparation
DE1154810B (de) 1961-04-01 1963-09-26 Knoll Ag Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
DE1643429A1 (de) * 1967-09-20 1971-01-28 Knoll Ag Basisch substituierte Phenylacetonitrile und Verfahren zu deren Herstellung
GB1202500A (en) 1967-12-08 1970-08-19 Knoll Ag Substituted phenylacetonitriles
GB1202750A (en) 1967-12-11 1970-08-19 Knoll Ag Substituted phenylacetonitriles
DE2059923C3 (de) 1970-12-05 1979-01-25 Knoll Ag, 6700 Ludwigshafen l-a-Isopropyl-o-[(N-methyl-N-homoveratryl)v-aminopropyl] -3,4-dimethoxyphenylacetonitril, Verfahren zu dessen Herstellung und dieses enthaltende Arzneimittel
DE2059985C3 (de) 1970-12-05 1979-10-04 Knoll Ag, 6700 Ludwigshafen Rechtsdrehende, basisch substituierte Phenylacetonitrile, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2946545A1 (de) * 1979-11-17 1981-05-27 Basf Ag, 6700 Ludwigshafen Verfahren zur gewinnung der enantiomeren formen von 4-cyan-1-(n-methyl-n-(2'-((3'',4'',-dimethoxyphenyl))-aethyl)-amino)-5-methyl-4-(3',4',5'-trimethoxyphenyl)-hexan und dessen salzen

Also Published As

Publication number Publication date
CA1184186A (en) 1985-03-19
ES521543A0 (es) 1984-02-01
FI76550B (fi) 1988-07-29
AU546383B2 (en) 1985-08-29
ES8402261A1 (es) 1984-01-16
PH19739A (en) 1986-06-23
DE3144150A1 (de) 1982-12-09
GB2100252B (en) 1984-06-27
ES8402560A1 (es) 1984-02-01
ES8402262A1 (es) 1984-01-16
ES521544A0 (es) 1984-01-16
EP0064158B1 (de) 1985-03-13
FI821252A0 (fi) 1982-04-07
SG78584G (en) 1985-04-26
NO152129C (no) 1985-08-07
NO821085L (no) 1982-10-11
GR75531B (es) 1984-07-26
AU8249082A (en) 1983-04-21
NO152129B (no) 1985-04-29
FI76550C (fi) 1988-11-10
US4438131A (en) 1984-03-20
EP0064158A1 (de) 1982-11-10
ES8307210A1 (es) 1983-07-01
ES521545A0 (es) 1984-01-16
DK156513B (da) 1989-09-04
IE54044B1 (en) 1989-05-24
CS238621B2 (en) 1985-12-16
CS238636B2 (en) 1985-12-16
ES511260A0 (es) 1983-07-01
SU1308195A3 (ru) 1987-04-30
DD201778A5 (de) 1983-08-10
DK159882A (da) 1982-10-11
HU186058B (en) 1985-05-28
GB2100252A (en) 1982-12-22
IE820856L (en) 1982-10-10
FI821252L (fi) 1982-10-11
DE3262516D1 (en) 1985-04-18
DK156513C (da) 1990-02-05
CS238634B2 (en) 1985-12-16
MX9203501A (es) 1992-09-01

Similar Documents

Publication Publication Date Title
CS238635B2 (en) Production method of new derivatives of omega-cyan-1-omega-diphenylazaalkane
EP0060674B1 (en) Dihydropyridine anti-ischaemic and antihypertensive agents, processes for their production, and pharmaceutical compositions containing them
EP0371731B1 (en) Quinazolinone derivatives
BG60428B2 (bg) Бензимидазоли,метод за получаването им и лекарствени средства, които ги съдържат
KR910000864B1 (ko) 신규의 의약품
EP0060897B1 (en) 1,4-dihydropyridine-3,5-dicarboxylic ester derivatives
US5679677A (en) Heterocyclic carbamates, process for their preparation and medicaments
IE49462B1 (en) New fluorine-containing 1,4-dihydropyridine compounds,their production and their medicinal use
US4814343A (en) Substituted 1H-imidazoles
US5198587A (en) Phenethylamine derivatives
GB2120251A (en) Dihydropyridines
US3898224A (en) 1,6,7,8-Tetrahydro-4-oxo-4H-pyrido {8 1,2-A{9 pyrimidine-9-carboalkoxy compounds
JPS5943460B2 (ja) ２−アミノ−６−ジアルキルアミノジヒドロピリジンの製造方法
US4304790A (en) 2-(Alkylthio, alkylsulfinyl or alkylsulfonyl)-4-[2-anilinoalkylamino)-1-hydroxyethyl]phenols and derivatives thereof
JPS58501124A (ja) フエニルアルキルオキシランカルボン酸、その製法、その使用及びそれを含有する医薬品
Franke et al. 2-(Isoxazolylethenyl) phenoxypropanolamines: a new class of. beta.-receptor antagonists with antihypertensive activity
KR950002154B1 (ko) 2-(아미노알킬티오)메틸-1,4-디히드로피리딘의 제조방법
JPH0419224B2 (es)
SU1470178A3 (ru) Способ получени производных @ -циано-1, @ -дифенилазаалканов или их кислотно-аддитивных солей
SU1213984A3 (ru) Способ получени производных @ -циано-1, @ -дифенилазаалканов (его варианты)
KR800000850B1 (ko) 1,4-디하이드로 피리딘 카복실산 아르알킬 에스테르의 제조방법
US4289769A (en) Derivatives of p-formylbenzamide amidinohydrazone and use thereof
US3961076A (en) α-Aminoalkyl-4-hydroxy-3-alkylsulfonylmethylbenzyl alcohols having β-adrenergic stimulant activity
HU193746B (en) Process for preparing 1,4-dihydropyridine derivatives
JPH0443913B2 (es)